GSK’s belantamab mafodotin meets primary objective in multiple myeloma trial

This article was originally published here

The company has reported positive headline results from the pivotal DREAMM-2 open-label and randomised study of two doses of belantamab mafodotin. Belantamab mafodotin is an immuno-conjugate, which included

The post GSK’s belantamab mafodotin meets primary objective in multiple myeloma trial appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply